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Subcutaneous Mucormycosis in an Immunocompetent
Nigerian Child
Abstract: A 13-year-old girl presented with a three–month history of generalized blisters on her body
following a traumatic injury to her leg with a piece of wood while farming. The lesions were hemorrhagic,
itchy and tender on pressure. The patient was non-diabetic, non-leukemic, non-neutropenic, and not previously
on immunosuppressive drugs, nor was there any evidence of immunosuppression. Culture and microscopic
examination of scrapings from the skin lesions revealed growth of a Mucor spp. She was initially placed on
potassium iodide and responded well for about a month, then relapsed. The patient was successfully treated
with itraconazole monotherapy.
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Introduction
Mucormycosis is a rare fungal infection seen most often in association with
prolonged neutropenia. Important information has also been collected by clinicians and
researchers regarding the association of zygomycosis with cancer (1), antibiotic or
prednisone use (2), diabetes (1,2), deferoxamine and desferrioxamine therapy (3),
transplantation (4), and combination of immunosuppressive therapies. Cases have also
been observed in immunocompetent hosts and have been noninvasive or locally invasive
without dissemination (5). With the development of diagnostic tools that allow earlier
diagnosis, better surgical and antifungal interventions, and more sophisticated
laboratory methods for identifying the offender agents, more patients are surviving
these previously fatal infections. In the treatment of Mucor infections, amphotericin B is
the drug of choice. In vitro testing has shown that both Mucor circinelloides and
Mucor hiemalis are susceptible to amphotericin B (6). Other reported treatments include
potassium iodide (1 g three times per day) for the treatment of subcutaneous lesions
(7).
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A 13-year-old girl was referred to us for skin lesions (blisters) covering most of the
body. The patient’s illness had started three months prior to presentation with traumatic
injury to the right leg while working on the farm. Initially, a blister had formed at the
site of the injury, which later ruptured to discharge a yellowish foul-smelling fluid. The
lesions had spread to the left leg and other parts of the body over the next two to three
months. They were itchy and bleeding, especially those around the joints. No history of
alcohol abuse, diabetes mellitus or leukemia was elicited. The patient was not receiving
any immunosuppressive therapy. On physical examination, she was found to be mildly
pale, afebrile and without peripheral lymphadenopathy. There were widespread
hyperpigmented skin lesions with scaling, scab formation and foul-smelling serous
discharge involving the lower and upper limbs, face, back, scalp and ears. The lesions
were interspaced with hypopigmented patches and spots (Figures 1 and 2). They were
hemorrhagic and varied in size. The rest of the physical examination was unremarkable.
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Figure 1. Skin lesions on left leg and left lower arm captured with
digital camera.
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Figure 2. Plaque of skin lesions on left upper and lower arms captured
with digital camera.

Initial tentative diagnoses were:
(i) Subcutaneous mycosis? Sporotrichosis. (ii) Skin
tuberculosis? Tuberculosis cutis verrucosa.
Complete blood count revealed a hemoglobin
concentration of 7gm% for which transfusion of packed
red blood cells was performed. Chemical pathological,
radiological and other hematological investigations
revealed no other abnormality. Mantoux test was
negative.
Scrapings from the skin lesions were dissolved with
10% potassium hydroxide on a clean glass-slide.
Aseptate, ribbon-like hyphae of irregular sizes (10- 40
μm) and numerous sclerotic bodies were seen scattered
throughout.
Cultures showed growth of a mold rapidly filling the
Petri dish of Sabouraud’s agar within 48 hours of
incubation with white luxurious colonies. The optimum
o
temperature for growth was 32–37 C; growth was poor
at room temperature (25oC). The colonies were examined
under light microscope.
The sporangia were globose with ellipsoidal
columellae that were partially obscured by
sporangiospores. Some sporangia were deliquescent
releasing clumps of hyaline sporangiospores. The hyphae
were broad and non-septate. Sporangiophores exhibited
minimal sympodial branching. Rhizoids and stolons were
absent (Figure 3).
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Figure 3. Lactophenol cotton blue (LPCB) mount of growth of Mucur
spp, on Sabouraud’s dextrose agar without cycloheximide.
Sporangiophores are seen with ellipsoidal columellae and
deliquescent sporangia releasing clumps of hyaline
sporangiospores (400x).

The diagnosis of mucormycosis in this case was based
on the presenting clinical features, cultural and
microscopic characteristics and morphology of the
fungus. The subspecies of the mucor has not been
identified since immunological and molecular diagnostic
investigations are yet to be done.
The patient was initially placed on potassium iodide
and responded well for about a month, then relapsed. She
was then successfully treated with itraconazole
monotherapy at a dose of 200 mg twice a day for 7
months. She is currently on follow-up.
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Discussion
Zygomycosis was first reported as a cause of human
disease in 1885 (8). Unlike other filamentous pathogens
that target immunocompromised hosts, zygomycosis
organisms infect a broader and more heterogeneous
population. Persons with no underlying conditions and
patients with diabetes mellitus represented >50% of all
infected patients (9). In a review of 929 cases of
zygomycosis by Roden et al. (10), cutaneous zygomycosis
was found to be the third most common type (19%)
after sinus (39%) and pulmonary (24%) zygomycosis.
Traumatic inoculation seems to be the means of
introduction of the fungal spores into the skin in our
patient. In this case, there was no underlying factor that
could be incriminated as a risk factor in development of
the disease. Although she was from the rural part of the
country and was of low socioeconomic background, she
was not malnourished. Another unusual experience with
our patient was the favorable manner in which she
responded to itraconazole monotherapy, as against the
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norm in which extensive debridement and amphotericin B
therapy constitute the gold standard. This may be due to
the fact that there was no evidence of dissemination of
the infection to deeper tissues and organs of the body.
Measures to decrease the incidence of zygomycosis in
patients at risk are difficult at best. There is no routine
antifungal prophylaxis available, and with the low
prevalence of zygomycosis, there is no real indication to
provide it. The most common preventive interventions
attempted involve modifications and controls in the
environment that reduce the risk of exposure to airborne
spores. Most of these control measures have focused on
easily identified patients at risk, i.e., those expected to be
profoundly neutropenic for prolonged periods.
Transplantation and chemotherapeutic wards are often
isolated with Hepa-filter treatment of the air supply and
positive pressure to exclude the recruitment of dust into
the ward (9). Adequate clothing and foot-wear are an
important protective measure for farmers.
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